"Bradenton Research Center is a dedicated research center led by Medical Director Eric Folkens, M.D. Our goal is to find better treatments than those already available for a wide variety of diseases. Since 1992, Bradenton Research Center has completed over 150 clinical research studies. The diseases we’ve studied include Alzheimer’s Disease, Influenza, Migraines, Neuropathic Pain, Gout, Hypertension, Stroke, Type 2 Diabetes, Diabetic Neuropathy, Epilepsy, COVID-19 and many others. It is fulfilling to see the significant progress in the treatments of the diseases we’ve studied. We’re currently engaged in more than a dozen studies that will continue to move us closer to finding better treatments and cures."

During the past decade, Bradenton Research Center conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 25 clinical trials were completed, i.e. on average, 104.2% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 17 clinical trials were completed. i.e. 154.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Bradenton Research Center" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Pfizer" with 5 trials sponsored, "Eisai Inc." with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bradenton Research Center" #1 collaborator was "Pfizer" with 4 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "APCER Life Sciences" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator and "Grifols Biologicals, LLC" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Bradenton Research Center" are "Alzheimer's Disease" (18 trials), "Alzheimer Disease" (5 trials), "Partial Epilepsy" (4 trials), "Parkinson's Disease" (3 trials) and "Diabetes Mellitus, Type 1" (2 trials). Many other conditions were trialed in "Bradenton Research Center" in a lesser frequency.

Most popular intervention types in "Bradenton Research Center" are "Drug" (49 trials), "Biological" (6 trials) and "Other" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Crenezumab" (3 trials), "Gantenerumab" (3 trials), "YKP3089" (3 trials) and "Bapineuzumab 0.5 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Bradenton Research Center" are 54 trials for "All" genders.

Currently, there are NaN active trials in "Bradenton Research Center". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Bradenton Research Center, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Bradenton Research Center, 1 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".